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Abstract
Background: The aim of this paper is to investigate the causality of the inverse associa-
tion between cigarette smoking and Parkinson’s disease (PD). The main suggested
alternatives include a delaying effect of smoking, reverse causality or an unmeasured
confounding related to a low-risk-taking personality trait.
Methods: A total of 715 incident PD cases were ascertained in a cohort of 220 494 individ-
uals from NeuroEPIC4PD, a prospective European population-based cohort study includ-
ing 13 centres in eight countries. Smoking habits were recorded at recruitment.
We analysed smoking status, duration, and intensity and exposure to passive smoking in
relation to PD onset.
Results: Former smokers had a 20% decreased risk and current smokers a halved risk of
developing PD compared with never smokers. Strong dose–response relationships with
smoking intensity and duration were found. Hazard ratios (HRs) for smoking <20 years
were 0.84 [95% confidence interval (CI) 0.67–1.07], 20–29 years 0.73 (95% CI 0.56–0.96)
and >30 years 0.54 (95% CI 0.43–0.36) compared with never smokers. The proportional
hazard assumption was verified, showing no change of risk over time, arguing against a
delaying effect. Reverse causality was disproved by the consistency of dose–response
relationships among former and current smokers. The inverse association between
passive smoking and PD, HR 0.70 (95% CI 0.49–0.99) ruled out the effect of unmeasured
confounding.
Conclusions: These results are highly suggestive of a true causal link between smoking
and PD, although it is not clear which is the chemical compound in cigarette smoking re-
sponsible for the biological effect.
Key words: Parkinson’s disease, smoking, smoking patterns, passive smoking, causal inference, cohort study,
EPIC, NeuroEPIC4PD
Key Messages
• The present data from the NeuroEPIC4PD study show a robust inverse association between smoking status at recruit-
ment and Parkinson’s disease (PD) risk with a dose–response relationship with smoking duration and intensity.
• These inverse relationships were replicated across different clinical subtypes.
• An inverse association between exposure to passive smoking at home and/or at work and risk of PD was also
identified.
• Explanation alternatives to a causal association including a delaying effect of smoking on disease onset, reverse cau-
sality, and unmeasured and residual confounding have been discussed in order to reinforce causal inference using
observational data.
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Background
An overwhelming amount of evidence exists on the inverse
association between cigarette smoking and Parkinson’s dis-
ease (PD). The inverse association is strong and consistent
across studies,1 stronger for current smokers than for for-
mer smokers when compared with non-smokers.1,2 Some
studies suggest that smoking duration is more strongly as-
sociated with a reduced risk of PD compared with smoking
intensity.3 The overall association appears consistent in
men and women1 and not confounded or modified by edu-
cational level. A comparable inverse association was also
observed for pipe and cigar smoking in men4 and for
smokeless tobacco.5,6 An attempt to demonstrate causality
of the association has been made using parental smoking
as an instrumental variable: it was shown that children of
smokers—who are more likely to smoke themselves—are
at decreased risk of PD even if they do not smoke.7
Nonetheless, there is still considerable caution in inter-
preting this association as protective. Few theories have
been postulated to explain the current evidence in a non-
causal way and these are summarized with Direct Acyclic
Graphs (DAGs) in Figure 1. Some studies failed to replicate
the association in cases with an older age of onset3,8 lead-
ing to the hypothesis that smoking might delay, not pre-
vent, PD onset (Figure 1B). The most intriguing, and more
difficult to prove, is a possible confounding effect by a
low-risk-taking personality trait that would be regarded as
an unmeasured confounder if it is genetically determined
or as reverse causation if it is triggered by dopamine
shortage9,10 (Figure 1C and D). According to this, and co-
herently with the involvement of dopamine in the brain-
rewarding circuits,11 people who will subsequently develop
PD tend to have a low-risk-taking personality, which
makes them less likely to smoke or more likely to quit.
Coherently, before disease onset, people with PD might
find it easier to quit smoking compared with those without
PD12 (Figure 1D). Nonetheless, the inverse association be-
tween smoking intensity and PD observed among monozy-
gotic twins argues against a major role of genetics and/or
personality.13 Given that personality trait would have a
lesser role in influencing the exposure to passive smoking,
demonstrating a decreased risk of PD among those exposed
to passive smoking would overcome this effect; however, a
previous study failed to find it.14
Figure 1. Direct Acyclic Graphs (DAGs) showing the hypotheses on the observed association between cigarette smoking and Parkinson’s disease.
(A) Smoking protects against PD (causal effect); (B) smoking delays PD onset; (C) subjects with a specific personality trait are both less likely to smoke
and more susceptible to PD (confounding effect); (D) subtle dopaminergic changes before disease onset make quitting smoking easier (reverse
causality).
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Clarifying the causal nature of the association between
smoking and PD would contribute to understanding the
mechanisms underlying the disease, informing potential tar-
gets for preventive or early treatments. Moreover, no data are
currently available on the consistency of the inverse associa-
tion between smoking and PD across clinical subtypes.
The aim of this study is to assess the association between
smoking patterns (duration, amount and time since quitting
smoking) and PD risk. Specifically, the potential delaying ef-
fect; the consistency of smoking patterns among current and
former smokers to interrogate any reverse causality; the as-
sociation with passive smoking; and the consistency of the
association across clinical subtypes will be investigated.
Methods
Population
The NeuroEPIC4PD study involved 220 494 subjects
recruited in Sweden, the UK, the Netherlands, Germany,
Spain, Italy and Greece from the general population resid-
ing in defined geographical areas between 1992 and 2002
and aged 37–70 years, within the European Presepctive
Investigation into Cancer and Nutrition (EPIC) study.15
Exception was the Utrecht cohort, which was based on
breast-cancer-screening participants.15 The Naples and
Utrecht cohorts were restricted to women, whereas all
other cohorts involved both sexes. To date, follow-up is
98.5% complete and the median follow-up time of this
sample is 12.8 years [inter-quartile range (IQR) 11.5–14.2].
Case ascertainment and sample size
A total of 881 PD cases was ascertained in the participat-
ing EPIC centres.16 The present analysis has been con-
ducted on a total sample of 214 533 subjects (including
715 incident PD cases) after removing 147 prevalent PD
cases, 5359 subjects (including 19 PD cases) with missing
information on smoking status at recruitment. Moreover,
221 subjects with PD-like conditions [Multi-System
Atrophy (MSA) N¼ 24; Progressive Sopra-nuclear Palsy
(PSP), N¼ 21; vascular parkinsonism, N¼ 34; Lewy Body
Dementia (LBD), N¼ 34; essential tremor, N¼27; PD
with essential tremor, N¼ 9; and unclassified parkinson-
ism, N¼ 72] were also removed from the analysis. The
sample resulted in a total of 2 666 206 person/years.
Procedures for PD case ascertainment in the EPIC cohort
have been described elsewhere.16 In brief, in each centre,
potential cases were identified through record linkage and
validated through clinical record review by a neurologist
expert in movement disorder who collected additional clin-
ical data, including age of onset (defined as age when the
first motor symptom was noticed) and clinical subtype at
onset (tremor-dominant, postural instability/gait distur-
bance, akinetic-rigid forms).16
Smoking characteristics
Answers to a number of questions on present and past
smoking habits were collected at recruitment in the EPIC
study. These included smoking status at recruitment
(never, former and current smoker), age when they started
smoking and quit, and number of cigarettes/day smoked at
different ages. This latter information was not collected in
Sweden, which was therefore excluded from all analyses
on smoking intensity (n¼ 53 291). Starting from this core
information, a number of variables were derived: duration
of smoking (never smokers, smokers for <20, 20–29,
30þ years) missing for 4620 individuals; smoking intensity
as mean lifetime cigarettes/day (never smokers, <12,
12þ cigarettes/day) missing for 10 876 individuals; time
since quitting smoking, namely number of years elapsed
from quitting smoking and recruitment to the cohort
(never smoker, 19þ, 9–18, <9 years) missing for 2221
individuals; age when quit smoking (never smoker, <33,
34–43, 44þ years) missing for 2221 individuals; and age
when started smoking (never smoker, 20þ, 17–19,
<16 years) missing for 3011 individuals. Information on
second-hand smoke (SHS) exposure was available only in a
few centres: participants were asked whether any of their
parents smoked when they were children in Italy, the
Netherlands and Sweden (N¼ 59 329), whereas informa-
tion on current SHS exposure at home or work was avail-
able only for participants recruited in Italy and Sweden
(N¼ 40 816).
Additional information collected at baseline and rele-
vant for this analysis is the highest educational level
attained (none/primary, technical, secondary, university).
Statistical analysis
Cox-regression models using age as the underlying time
variable, adjusted for level of education and sex, and strati-
fied for centre and age at recruitment, were run in order to
investigate the effects of the main smoking variables in re-
lation to PD onset. Models investigating smoking status,
duration and amount of smoking, time and age since quit-
ting smoking for former smokers and age when started
smoking were investigated and p-values for trend across
categories calculated where appropriate. Analyses were re-
peated using never smokers as the reference category where
appropriate, in men and women separately, and restricted
to tremor-dominant and akinetic-rigid forms of PD at
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onset. Heterogeneity across country was tested using the
approach proposed by Smith et al.17 Heterogeneity was
assessed by the likelihood ratio of two stratified models:
one with country-specific estimates and one with overall
estimates. Under the null hypothesis of no heterogeneity,
this statistic follows approximately a chi-square distribu-
tion on (k – 1)*(j – 1) degrees of freedom (where k is the
number of categories of smoking variable and j is the total
number of countries).
In order to investigate a potential delaying effect of
smoking on PD onset, possible non-proportionality was
assessed using the Schoenfeld residuals.18 Also, the analysis
on the main three smoking variables was repeated on the
mid-age of PD onset after excluding subjects with an onset
at 70þ years (<70 years, N¼ 385) or on late PD onset, af-
ter excluding those with an age of onset younger than
70 years (70þ years, N¼ 330). Studying separately subjects
with a young age at onset (50 years) was not possible, as
there were only 12 such cases.
For indirectly exploring reverse causality, the Cox
regression exploring the dose–response relationships between
smoking intensity and duration were repeated among current
and former smokers at recruitment separately.
Both variables on SHS (in infancy and at recruitment)
where studied in relation to PD onset in Cox-regression
models repeated in never smokers only in an attempt to
overcome unmeasured and residual confounding of the
main association.
Finally, for exploring the possible competing risk of
mortality in the smoker group, a competing-risk survival
analysis was carried out using death as a competing event
and the Fine and Gray regression model.19
A sensitivity analysis was conducted repeating the main
Cox models using definite and very likely PD diagnosis only
(389 PD cases). For further detail on how cases were labelled,
please refer to the methodological paper.16 All analyses were
done using STATA 12 IC and R version 3.3.2 (R Foundation
for Statistical Computing, Vienna, Austria).
No direct patient involvement was needed to run this
study, which was based on data previously collected.
Results
Demographic characteristics and smoking habits for men
and women in the EPIC cohort and PD cases are described
in Table 1. Former smokers at recruitment had a 20% re-
duced risk of developing PD during follow-up compared
with never smokers; current smokers had a halved risk
compared with never smokers (Table 2). These results
were highly consistent in men and women (Table 3) and no
heterogeneity was detected across countries (Table 4). The
difference in incidence rates across countries is more likely
due to local differences in case-ascertainment procedures
rather than true difference in incidence, as discussed in.16
Studied individually, all smoking variables were found
to be inversely associated with the risk of PD with clear-
cut dose–response relationships. For age when started and
quit smoking, a monotonic trend across categories was not
evident (Table 2). The analysis of residuals of Schonefeld
showed no evidence of non-proportionality over the
follow-up period. The smoothed curves for former smokers
(Figure 2A) and for current smokers (Figure 2B) were flat,
showing that beta-coefficient (log hazard ratio) estimates
did not vary during follow-up (time) (Figure 2). Smoking
variables were associated with inverse risk of both mid-age
and late-onset PD; however, all the estimates are stronger
in the latter. All the risk estimates, conversely, remain
highly consistent for the akinetic-rigid and tremor-
dominant forms at onset (Table 5). The Postural
Instability/Gait Disturbance (PIGD) form could not be
studied individually, as it included only 42 subjects.16
The competing-risk analysis using mortality as a com-
peting factor yielded much stronger point estimates but
largely overlapping 95% confidence intervals (CIs) for all
the active smoking variables: smoking for 30þ years or
12þ cigarettes/day is associated with a 55% reduced risk
of PD compared with never smokers (Table 2).
Hazard ratios (HRs) of smoking intensity and duration
from Cox models stratified for smoking status at recruit-
ment are shown in Figure 3. Point estimates in current
smokers are consistently lower compared with those in for-
mer smokers, although the pattern of risk reduction is
highly comparable across the two groups, all trends had
p 0.001 and no interaction was detected between smok-
ing duration and intensity and smoking status (p-value for
interaction 0.823 and 0.537, respectively).
Analysis of passive smoking, although hampered by
limited power, showed no association between exposure to
passive smoking in infancy and risk of PD. However, an in-
verse association was found between passive-smoking ex-
posure at home or at work and risk of PD (HR 0.70, 95%
CI 0.49–0.99), which was replicated among never smokers
only (HR 0.71, 95% CI 0.46–1.10).
The sensitivity analysis including definite and very likely
PD only yielded strikingly similar results (Table 3). All
associations were, if anything, strengthened despite the
widening of CIs due to the smaller sample size. An inverse
association between age when quitting smoking and risk of
PD was also suggested by the sensitivity analysis.
Discussion
This study provides unique data on the inverse association
between cigarette smoking and risk of PD in a large, well-
International Journal of Epidemiology, 2018, Vol. 00, No. 00 5
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established cohort study, supporting previous findings,3,4,8
and allows testing of explanations other than a direct
protective effect. Overall, data coming from the
NeuroEPIC4PD study show a robust inverse association
between smoking status at recruitment and PD risk, with a
dose–response relationship between PD risk and smoking
duration and intensity. Of particular interest is the replica-
tion of the main findings of the inverse relationship be-
tween smoking and PD among different subtypes of the
disease. This is a novel finding, as, to our knowledge, clini-
cal subtypes have not been investigated to date in such an
epidemiological setting.
Table 1. Demographic characteristics and smoking habits among men and women with and without PD at recruitment in the
EPIC Study
Total Men Women
N¼214 533 N¼80 389 N¼134 144
PD Cohort PD Cohort PD Cohort
N¼715 N¼213 818 N¼366 N¼80 023 N¼349 N¼133 795
Age at recruitment, mean (SD) 61.4 (8.3) 53.0 (10.0) 61.7 (8.3) 53.1 (10.1) 61.3 (8.3) 53.0 (9.9)
Age at onset, mean (SD)a 67.5 (7.9) 67.6 (7.8) 67.3 (8.0)
Smoking status at recruitment
Never smoker, % 402 (56.2) 101 958 (47.7) 149 (40.7) 26 969 (33.7) 253 (72.5) 74 989 (56.1)
Former smoker, % 232 (32.5) 59 653 (27.9) 165 (45.1) 29 976 (37.5) 67 (19.2) 29 677 (22.2)
Current smoker, % 81 (11.3) 52 207 (24.4) 52 (14.2) 23 078 (28.8) 29 (8.3) 29 129 (21.8)
Duration of smokingb
<20 years, % 92 (32.4) 36 243 (33.8) 57 (28.6) 15 013 (29.6) 35 (41.2) 21 230 (37.6)
20–29 years, % 69 (24.3) 32 425 (30.2) 47 (23.6) 15 171 (29.9) 22 (25.9) 17 254 (30.5)
30þ years, % 123 (43.3) 38 601 (36.0) 95 (47.7) 20 551 (40.5) 28 (32.9) 18 050 (31.9)
Lifetime cigarettes/dayc
<12 cigarettes/day, % 91 (50.3) 35 132 (47.8) 56 (41.5) 11 085 (31.2) 35 (76.1) 24 047 (63.4)
12þ cigarettes/day, % 90 (49.7) 38 370 (52.2) 79 (58.5) 24 478 (68.8) 11 (23.9) 13 892 (36.6)
Time since quitting smokingd
19þ years, % 110 (50.7) 19 737 (34.4) 82 (52.9) 10 151 (35.3) 28 (45.2) 9586 (33.5)
9–18 years, % 58 (26.7) 19 295 (33.6) 40 (25.8) 9773 (33.9) 18 (29.0) 9522 (33.2)
<9 years, % 49 (22.6) 18 415 (32.1) 33 (21.3) 8874 (30.8) 16 (25.8) 9541 (33.0)
Age when quit smokingd
<33 years, % 54 (24.9) 18 330 (31.9) 44 (28.4) 8 354 (29.0) 10 (16.1) 9 976 (34.8)
33–43 years, % 53 (24.4) 19 086 (33.2) 33 (21.3) 9809 (34.1) 20 (32.3) 9277 (32.4)
44þ years, % 110 (50.7) 20 031 (34.9) 78 (50.3) 10 635 (369) 32 (51.6) 9396 (32.8)
Age when started smokinge
20þ years, % 136 (46.0) 43 194 (36.7) 75 (36.1) 17 192 (33.3) 61 (69.3) 26 002 (45.4)
17–19 years, % 74 (25.0) 31 984 (29.4) 61 (29.3) 14 975 (29.0) 13 (14.8) 17 009 (29.7)
<16 years, % 86 (29.1) 33 688 (30.9) 72 (34.6) 19 458 (37.7) 14 (15.9) 14 230 (24.9)
Educational levelf
None/primary, % 389 (56.1) 94 988 (44.8) 192 (54.1) 33 823 (42.7) 197 (58.3) 61 165 (46.1)
Technical, % 148 (21.4) 46 407 (21.9) 73 (20.6) 18 173 (22.9) 75 (22.2) 28 234 (21.3)
Secondary, % 69 (10.0) 33 145 (15.7) 38 (10.7) 11 788 (14.9) 31 (9.2) 21 357 (16.1)
University or above, % 87 (12.6) 37 275 (17.6) 52 (14.7) 15 463 (19.5) 35 (10.4) 21 812 (16.5)
Passive smoking
In childhoodg, % 100 (64.1) 42 491 (71.8) 36 (67.9) 8101 (66.4) 64 (62.1) 34 390 (73.2)
At home or at workh, % 86 (62.3) 27 941 (68.7) 34 (63.0) 9102 (74.6) 52 (61.9) 18 839 (66.1)
a233 missing values (138 men and 85 women).
bCalculated on ever smokers only, 4620 missing values.
cCalculated on ever smokers only after excluding Swedish subjects (N¼ 53 291), 10 876 missing values.
dCalculated on former smokers only, 2221 missing values.
eCalculated on ever smokers only, 3011 missing values.
fNot including 2025 subjects with undetermined educational level.
gAvailable for 59 329 individuals only.
hAvailable for 40 816 individuals only.
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Delaying effect of smoking
The fact that proportional assumption hypothesis is verified
demonstrates that the risk does not vary over the follow-up
period, and this argues against a delaying effect of smoking
on PD onset (Figure 1B). Moreover, at odds with some pre-
vious reports,3,8 our findings of an inverse relationship
between smoking variables and risk of PD are not weakened
when the analysis is restricted to old-age onset PD
(70þ years). Taken together, these results are not supportive
of the hypothesis that smoking might delay, rather than pre-
vent, PD onset, as previously suggested.3,8 However, despite
this piece of evidence being important and informative per
Table 2. Cox-regression analyses showing hazard ratios (HRs) [and relative 95% confidence intervals (CIs)] and using as refer-
ence category never smokers or the appropriate category for each variable and HRs (and 95% CIs) for competing-risk models
using mortality as competing risk
PD cases HR (95% CI) HR (95% CI) Competing-risk HR (95% CI)a
Smoking status at recruitment
Never smokers 402 1.00 1.00
Former smokers 232 0.79 (0.66–0.94) 0.75 (0.63–0.89)
Current smokers 81 0.49 (0.38–0.63) 0.44 (0.35–0.57)
Duration of smokingb
Never smokers 402 1.00 1.00
<20 years 92 0.84 (0.67–1.07) 1.00 0.81 (0.64–1.02)
20–29 years 69 0.73 (0.56–0.96) 0.87 (0.63–1.19) 0.67 (0.51–0.87)
30þ years 123 0.54 (0.43–0.66) 0.61 (0.46–0.80) 0.49 (0.40–0.61)
<0.001 <0.001 <0.001
Smoking intensityc
Never smokers 284 1.00 1.00
<12 cigarettes/day 91 0.80 (0.62–1.02) 1.00 0.77 (0.60–0.98)
12þ cigarettes/day 90 0.54 (0.42–0.71) 0.69 (0.50–0.94) 0.49 (0.38–0.64)
<0.001 0.020 <0.001
Time since quit smokingd
Never smokers 402 1.00 1.00
19þ years 110 0.87 (0.69–1.09) 1.00 0.85 (0.68–1.06)
9–18 years 58 0.71 (0.53–0.95) 0.81 (0.58–1.12) 0.65 (0.49–0.87)
<9 years 49 0.68 (0.50–0.93) 0.80 (0.56–1.14) 0.65 (0.48–0.88)
0.002 0.173 <0.001
Age when quit smokingd
Never smokers 402 1.00 1.00
<33 years 54 0.94 (0.70–1.26) 1.00 0.90 (0.67–1.20)
34–43 years 53 0.71 (0.52–0.95) 0.76 (0.52–1.12) 0.69 (0.51–0.93)
44þ years 110 0.74 (0.59–0.93) 0.78 (0.55–1.11) 0.69 (0.55–0.87)
0.003 0.217 <0.001
Age when started smokinge
Never smokers 402 1.00 1.00
20þ years 136 0.74 (0.61–0.91) 1.00 0.70 (0.57–0.85)
17–19 years 74 0.59 (0.45–0.76) 0.76 (0.56–1.03) 0.56 (0.44–0.72)
<16 years 86 0.63 (0.49–0.81) 0.78 (0.58–1.05) 0.57 (0.45–0.73)
<0.001 0.095 <0.001
Passive smoking in childhood 56 1.00 1.00
100 0.99 (0.71–1.40) 0.97 (0.69–1.36)
0.995 0.862
Passive smoking at home/work 52 1.00 1.00
86 0.70 (0.49–0.99) 0.71 (0.50–1.01)
0.047 0.059
aRestricted to the whole cohort except Sweden.
bCalculated after excluding 4620 (of which 29 PD) missing values.
cCalculated after excluding 10 876 missing values (of which 55 PD cases).
dCalculated after excluding 54 509 (of which 96 PD cases) missing values.
eCalculated after excluding 3011 (of which 17 PD cases) missing values.
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se, the distinction between delaying and preventing any dis-
ease onset is somewhat artificial, as these mechanisms might
coincide from both a clinical and a biological point of view.
Reverse causality
If an inverse causal relationship—accounting for subjects
with a preclinical dopaminergic change who therefore
might find it easier to quit smoking—was responsible for
the observed inverse association between smoking and PD,
the dose–response relationship between smoking duration
and intensity should not hold true among former smokers
(Figure 1C). The fact that the risk of PD was reduced
among current and former smokers argues against this pos-
sible explanation. Furthermore, the inverse association be-
tween time since cessation and PD reinforces the idea that
reverse causality is not a likely explanation of the findings:
having quit smoking 9–18 years before recruitment into the
study (therefore up to 30 years before disease onset)
still confers a reduced risk of PD compared with never
Table 3. Hazard ratios (HRs) and relative 95% confidence intervals (CIs) from Cox-regression models investigating smoking vari-
ables in relation to PD onset in men and women separately and sensitivity analysis including only definite and very likely PD
cases
Men Women All
PD cases HR (95% CI)a PD cases HR (95% CI)a Definite and very
likely PD cases
HR (95% CI)a
Smoking status at recruitment
Never smokers 149 1.00 253 1.00 228 1.00
Former smokers 165 0.77 (0.62–0.97) 67 0.80 (0.60–1.07) 121 0.85 (0.66–1.08)
Current smokers 52 0.49 (0.35–0.67) 29 0.46 (0.31–0.69) 40 0.42 (0.29–0.59)
Duration of smoking
Never smokers 149 1.00 253 1.00 228 1.00
<20 years 57 0.83 (0.61–1.14) 35 0.83 (0.58–1.21) 55 0.98 (0.72–1.34)
20–29 years 47 0.76 (0.54–1.06) 22 0.68 (0.43–1.07) 33 0.64 (0.44–0.94)
30þ years 95 0.55 (0.42–0.72) 28 0.45 (0.30–0.67) 64 0.52 (0.39–0.70)
Trend <0.001 Trend <0.001 Trend <0.001
Smoking intensityb
Never smokers 149 1.00 253 1.00 228 1.00
<12 cigarettes/day 56 0.79 (0.57–1.10) 35 0.83 (0.58–1.25) 51 0.85 (0.61–1.19)
12þ cigarettes/day 79 0.56 (0.42–0.76) 11 0.53 (0.28–0.99) 46 0.47 (0.33–0.68)
Trend <0.001 Trend 0.043 Trend <0.001
Time since quitting smoking
Never smoker 149 1.00 253 1.00 228 1.00
19þ years 82 0.89 (0.67–1.18) 28 0.79 (0.53–1.19) 58 1.05 (0.77–1.44)
9–18 years 40 0.68 (0.48–0.97) 18 0.78 (0.48–1.27) 28 0.67 (0.45–1.01)
<9 years 33 0.66 (0.45–0.97) 16 0.73 (0.44–1.23) 30 0.75 (0.50–1.11)
Trend 0.008 Trend 0.106 Trend 0.046
Age when quitting smoking
Never smoker 149 1.00 253 1.00 228 1.00
<33 years 44 1.10 (0.78–1.55) 10 0.56 (0.29–1.07) 36 1.25 (0.86–1.80)
34–43 years 33 0.60 (0.41–0.88) 20 0.96 (0.60–1.53) 28 0.74 (0.49–1.11)
44þ years 78 0.72 (0.54–0.97) 32 0.77 (0.52–1.12) 52 0.73 (0.53–1.01)
Trend 0.006 Trend 0.164 Trend 0.032
Age when started smoking
Never smoker 149 1.00 253 1.00 228 1.00
20þ years 75 0.71 (0.53–0.94) 61 0.77 (0.57–1.04) 67 0.70 (0.52–0.93)
17–19 years 61 0.70 (0.51–0.95) 13 0.36 (0.20–0.64) 38 0.58 (0.41–0.84)
<16 years 72 0.63 (0.47–0.84) 14 0.58 (0.33–1.02) 52 0.73 (0.53–1.01)
Trend 0.001 Trend <0.001 Trend 0.006
Passive smoking in childhood 53 1.25 (0.70–2.24) 103 0.88 (0.60–1.32)
Passive smoking at home/work 54 0.71 (0.40–1.23) 84 0.68 (0.43–1.08)
aModels adjusted for educational level and sex (where appropriated) and stratified by centre and age at recruitment.
bExcluding Sweden (N¼ 53 291) and missing for 10 876 subjects who were excluded from this model.
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smokers. This results are in line with previous observa-
tional studies that showed an inverse association between
parental smoking and PD in the offspring;7 also, the use of
parental smoking as an instrumental variable overcomes
the potential for a reverse-causality effect.
Unmeasured confounding
Whereas it was not possible to account for personality
trait, its unmeasured confounding effect can be overcome
by using exposure to passive smoking in relation to PD on-
set. Risk propensity is likely to influence one’s attitude to-
wards active smoking, whereas passive smoking is more
likely to be related to these personal characteristics in a
weaker way (e.g. smokers tend to have smoking partners).
The inverse association between passive smoking and PD
onset, whose point estimate has been replicated among
never smokers only, argues against considering personality
trait as a major confounder. These results are in line with
previous reports showing how adjusting for sensation-
seeking score only slightly attenuated the inverse associa-
tion between smoking and PD suggesting an independent
effect20 and with observations that personality traits such
as neuroticism and introversion do not explain the inverse
association between smoking and PD risk.21
Biological plausibility
A number of substances present in tobacco have been
proposed as potentially responsible for the inverse
Figure 2. Analysis of the residuals of Schoenfeld residuals to assess the proportionality assumption comparing former smokers (A) and current smok-
ers (B) with never smokers. Figures represent plots of beta-coefficient estimates (log hazard ratios) for former smokers (A) and current smokers (B)
against follow-up (time) in years. The darker (blue) line represents a smoothed curve of scaled Shoenfeld residuals with 95% confidence intervals
(darker (blue) dotted lines), whereas the lighter (red) line represents a beta-coefficient estimate from a Cox-regression model.
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association between smoking and PD. One of these is
2,3,6-trimethyl-1,4-naphthoquinone (TMN), an inhibi-
tor of monoamine oxidase (MAO) A and B activity.22
TMN partially protects against 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced neurode-
generation in mice by reducing endogenous dopamine
metabolism and consequently decreasing oxidative
stress. Synthetic MAO B inhibitors are currently used in
the treatment of PD, providing symptomatic relief, but
they may also protect against nigrostriatal damage de-
creasing dopamine metabolism, as suggested by delayed
need for antiparkinsonian drugs in a recent clinical tri-
al.23 Another candidate is nicotine itself, given the close
anatomical relationship between the nicotinic choliner-
gic and dopaminergic neurotransmitter systems in the
striatum. Nicotine influences also the dopaminergic ac-
tivity by acting at nicotinic receptors on dopaminergic
terminals and modulating dopamine release.24,25
The role of nicotine is being investigated in a random-
ized trial in patients with early PD, but a role of other
tobacco components cannot be excluded.
Being exposed to passive smoke is associated with a
reduced risk of 30% (HR 0.70, 95% CI 0.49–0.99) and be-
ing a light smoker with a 20% reduced risk (HR 0.80,
95% CI 0.62–1.02) (Table 2). Although the difference
could be due to limits in the design (data on passive smok-
ing were available for a subset of the sample), it cannot be
excluded that passive smoking has a stronger effect than
one would expect from a pure equivalence of levels of ex-
posure. Passive smoking has been demonstrated to be as
mutagenic as active smoking,26 although earlier studies
suggest that the overall chemical composition of passive
smoking might not represent only the diluted composition
of side-stream smoking, given the sorbing and desorbing
properties of some volatile and semi-volatile organic com-
pounds in passive smoking.27
The main strengths of this study are the prospective de-
sign, the validated clinical outcome,28 the large sample and
the detailed information on smoking patterns. This
allowed a powered recall-bias-free analysis of smoking pat-
terns in relation to PD onset. The main limitation of this
study, however, is the lack of repeated smoking measure-
ments over time, which might introduce some exposure
misclassification, decreasing our ability to study smoking
patterns in relation to PD onset. This is particularly true
for outcomes ascertained many years after recruitment.
However, the smoking pattern analyses repeated separately
for PD cases ascertained within and after 8 years since re-
cruitment yield highly consistent results (data not shown).
Conclusions
In conclusion, the present findings are consistent with a
protective effect of smoking on the risk of PD. Point esti-
mates of smoking status are strong, with a strong
exposure–response relationship of smoking intensity and
Table 5. Hazard ratios (HRs) and relative 95% confidence intervals (CIs) for Cox regressions analysing risk of PD at early and
older age of onset and in tremor-dominant or akinetic-rigid forms
Mid-age PD onset Late PD onset Tremor-dominant PDa Akinetic-rigid PDa
PD HR PD HR PD HR PD HR
(N¼385) (95% CI) (N¼330) (95% CI) (N¼234) (95% CI) (N¼157) (95% CI)
Smoking status at recruitment
Never smoker 215 1.00 187 1.00 140 1.00 102 1.00
Former smoker 119 0.89 (0.70–1.14) 113 0.69 (0.53–0.89) 66 0.84 (0.61–0.16) 38 0.66 (0.44–0.98)
Current smoker 51 0.51 (0.37–0.69) 30 0.48 (0.32–0.72) 28 0.47 (0.31–0.73) 17 0.39 (0.23–0.67)
Duration of smoking
Never smokers 215 1.00 187 1.00 140 1.00 102 1.00
<20 years 56 0.90 (0.67–1.23) 36 0.76 (0.53–1.11) 34 1.00 (0.67–1.49) 16 0.64 (0.37–1.10)
20–29 years 37 0.68 (0.47–0.97) 32 0.81 (0.55–1.21) 25 0.82 (0.52–1.30) 11 0.49 (0.26–0.93)
30þ years 66 0.60 (0.45–0.81) 57 0.47 (0.34–0.64) 31 0.46 (0.30–0.69) 27 0.53 (0.34–0.84)
<0.001 <0.001 <0.001 0.002
Smoking intensityb
Never smokers 154 1.00 130 1.00 91 1.00 62 1.00
<12 cigarettes/day 50 0.84 (0.60–1.18) 41 0.74 (0.51–1.08) 28 0.93 (0.58–1.47) 14 0.58 (0.31–1.07)
12þ cigarettes/day 55 0.62 (0.44–0.87) 35 0.46 (0.31–0.69) 20 0.46 (0.27–0.78) 18 0.50 (0.27–0.91)
0.006 <0.001 0.007 0.014
aInformation on subtype is not available for 324 PD cases.
bRestricted to the whole cohort except Sweden.
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duration. The consistency across different disease subtypes
suggests that the putative protective effect might spread to
the entire clinical spectrum of the disease. Finally, the in-
verse association found between passive smoking and PD
is supported by a consistent finding among never smokers
and points towards a true biological effect not mediated by
personality type. Although smoking to prevent PD cannot
be recommended given the multiple adverse effects of
smoking, our results confirming an inverse association
warrants further research on the mechanisms involved. In
particular, the use of Mendelian randomization and bio-
markers of long-term cigarette-smoke exposure should
provide compelling final evidence on the inverse associa-
tion between smoking and PD.
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